Isis Pharmaceuticals, Inc. (NASDAQ:ISIS) today announced that the company has entered into a global collaboration with Janssen Biotech, Inc. (Janssen) to discover and develop antisense drugs to treat autoimmune disorders of the gastrointestinal (GI) tract. The collaboration brings together Isis’ RNA-targeted technology platform and the expertise of Janssen in autoimmune disorders and therapeutic formulation to discover and develop antisense drugs that can be locally administered, including oral delivery, t… Read more
Shares of Isis Pharmaceuticals closed last Friday at $61.57 . ISIS has a 1-year high of $67.12 and a 1-year low of $22.25. The stock’s 50-day moving average is $56.52 and it’s 200-day moving average is $42.15.
On the ratings front, Isis Pharmaceuticals has been the subject of a number of recent research reports. In a report published on December 16, analyst Cory Kasimov from J.P. Morgan assigned a Hold rating to ISIS, with a price target of $65, which implies an upside of 5.6% from current levels. Separately, on December 10, Piper Jaffray`s Joshua Schimmer assigned a Buy rating to Isis Pharmaceuticals shares.
One research analyst has assigned a Hold rating and 5 research analysts have given a Buy rating to the stock. When considering if perhaps the stock is under or overvalued, the average price target is 61.57$ which is 9.5% above where the stock closed last Friday.
Isis Pharmaceuticals is engaged in antisense drug discovery and development, exploiting a novel drug discovery platform it created to generate a broad pipeline of first-in-class drugs.